Related Experiment Video
Updated: Nov 7, 2025
Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures
Aistė Gulla, Egidijus Kazlauskas1, Hong Liang2
1Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
Objectives:
Pancreatic ductal adenocarcinoma is one of the deadliest cancers for which few curative therapies are available to date. Heat shock protein 90 (Hsp90) inhibitors have shown activity against numerous cancers in vitro; therefore, we tested whether they could be used to target pancreatic ductal adenocarcinoma.
Methods:
Inhibitors of Hsp90 ATPase activity were applied on low-passage pancreatic cell line cultures (Panc10.05, Panc215, A6L) in a dose-response manner, and the inhibitor in vitro effect on cell growth was evaluated. Seven of novel Hsp90 inhibitors based on resorcinol fragment and 5 commercially available Hsp90 inhibitors (17-AAG, AT-13387, AUY-922, ganetespib, and rifabutin) as well as control compound triptolide were tested yielding IC50 values in 2- and 3-dimensional assays.
Results:
The novel Hsp90 inhibitors exhibited strong effects on all 3 tested pancreatic cell line cultures (Panc10.05, Panc215, A6L) reaching the IC50 of 300 to 600 nM in 2- and 3-dimensional assays.
Conclusions:
Novel Hsp90 inhibitors can be developed as antipancreatic cancer agents. Their chemical structures are simpler, and they are likely to exhibit lower side effects than the much more complex inhibitors used as controls.
Insights
Novel Heat shock protein 90 (Hsp90) inhibitors show promise against pancreatic cancer. These new agents are simpler and may have fewer side effects than existing treatments, offering a potential new therapy for pancreatic ductal adenocarcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Pancreatic ductal adenocarcinoma is a highly lethal cancer with limited therapeutic options.
- Heat shock protein 90 (Hsp90) is a molecular chaperone implicated in cancer cell survival and proliferation.
- Hsp90 inhibitors have demonstrated anti-cancer activity in various tumor types.
Purpose of the Study:
- To evaluate the efficacy of novel Hsp90 inhibitors against pancreatic ductal adenocarcinoma cells.
- To compare the activity of novel resorcinol-based Hsp90 inhibitors with commercially available ones.
Main Methods:
- Three pancreatic cancer cell lines (Panc10.05, Panc215, A6L) were treated with novel and commercial Hsp90 inhibitors.
- In vitro dose-response assays were conducted in 2D and 3D cultures.
- Half maximal inhibitory concentration (IC50) values were determined.
Main Results:
- Novel Hsp90 inhibitors demonstrated significant anti-proliferative effects on all tested pancreatic cancer cell lines.
- IC50 values for novel inhibitors ranged from 300 to 600 nM in both 2D and 3D assays.
- Commercial Hsp90 inhibitors and triptolide were also tested for comparison.
Conclusions:
- Novel Hsp90 inhibitors represent a potential new therapeutic strategy for pancreatic cancer.
- The simpler chemical structure of novel inhibitors may lead to reduced side effects compared to existing agents.
- Further development of these novel Hsp90 inhibitors is warranted for pancreatic cancer treatment.
